{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-114226","form_type":"8-K","ticker":"OGN","cik":"0001821825","company_name":"Organon & Co.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.349598+00:00","generated_at":"2026-06-22T09:47:36.736967+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Organon Q3 revenues $1.54B (-4% YoY); raises FY adjusted EBITDA margin guidance","bullets":["Q3 revenue $1,537M, down 4% YoY as-reported but up 3% ex-FX.","GAAP diluted EPS $0.89, non-GAAP adjusted diluted EPS $1.32.","Women's Health revenue grew 19% (23% ex-FX) on Nexplanon demand.","Full year 2022 revenue guidance narrowed to $6.1-$6.2B; adjusted EBITDA margin raised to 33.5%-34.5%.","Board declares quarterly dividend of $0.28 per share."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-114226","json":"https://secwatch.observer/filing/0001104659-22-114226.json","markdown":"https://secwatch.observer/filing/0001104659-22-114226.md","text":"https://secwatch.observer/filing/0001104659-22-114226.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821825/000110465922114226/0001104659-22-114226-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821825/000110465922114226/tm2229543d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:47:36.736967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b7138713ef9c0cb39fcc54d18f3c818db340f30","claim":"Organon & Co. reported the third quarter ended September 30, 2022 results: revenue $1,537 million, net income 227, EPS $0.89.","evidence_excerpt":"Halchak (614) 314-8094 Kate Vossen (732) 675-8448 (201) 275-2711 Organon rep orts results for the third quarter ended September 30, 2022 · Third quarter 2022 revenues of $1,537 million · Third quarter diluted earnings per share from continuing operations of $0.89 and non-GAAP adjusted diluted earnings per share from continuing operations of $1.32 · Both","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821825/000110465922114226/0001104659-22-114226-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$1,537 million"},{"label":"Net income","value":"227"},{"label":"EPS","value":"$0.89"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}